These are the drugs that lose their U.S. patents in 2025: most are in common use across the country by millions of people
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...